How is liraglutide dosed?
| Product | Strength | Pen | Doses delivered |
|---|---|---|---|
| Victoza | 6 mg/mL | 18 mg in 3 mL | 0.6, 1.2 or 1.8 mg1 |
| Saxenda | 6 mg/mL | 3 mL | 0.6, 1.2, 1.8, 2.4 or 3 mg2 |
What the pens hold and whether liraglutide is mixed
The table is set at the top of the page
Both labels give a ready 6 mg/mL solution in a prefilled pen; the Victoza carton lists pens, no pen needles and no mixing step.12 The EMA text says one Victoza pen delivers 30 doses of 0.6 mg, 15 of 1.2 mg or 10 of 1.8 mg.3 The volumes below are arithmetic on the labels' 6 mg/mL strength, not label figures.12
| Dose | Volume at 6 mg/mL |
|---|---|
| 0.6 mg | 0.1 mL |
| 1.2 mg | 0.2 mL |
| 1.8 mg | 0.3 mL |
| 2.4 mg | 0.4 mL |
| 3 mg | 0.5 mL |
Victoza dose and step-up
For adults with type 2 diabetes, the Victoza label starts at 0.6 mg once daily for one week, then 1.2 mg daily, then 1.8 mg daily after one week at 1.2 mg if additional glycemic control is required.1 For pediatric patients aged 10 years and older with type 2 diabetes, the label starts at 0.6 mg once daily for at least one week, then 1.2 mg daily if additional glycemic control is required, then 1.8 mg daily after at least one week at 1.2 mg if it is still required.1
Saxenda dose and step-up
The Saxenda label gives 0.6 mg daily in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4 and 3 mg in week 5 and onward.2 For adults the label gives 3 mg daily, with lower doses for titration only, and says efficacy below 3 mg daily has not been established for weight reduction.2 For pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, the label gives a maintenance dosage of 3 mg daily, or 2.4 mg daily if 3 mg is not tolerated.2 The US label says to evaluate body weight 16 weeks after starting and to stop if at least 4% of baseline body weight has not been lost.2
How often liraglutide is given and where
Both US labels give it subcutaneously once daily at any time of day, independent of meals, in the abdomen, thigh or upper arm.12
Doses in the trials and weight change
| Trial | Dose and schedule (once daily unless stated) | People | Length |
|---|---|---|---|
| SCALE Obesity and Prediabetes (Pi-Sunyer, 2015)45 | 3.0 mg, or placebo, both with counseling on lifestyle modification | 2487 on liraglutide, 1244 on placebo; 3731 patients without type 2 diabetes, BMI at least 30, or at least 27 with dyslipidemia or hypertension | 56 weeks |
| SCALE Diabetes (Davies, 2015)67 | 3.0 mg or 1.8 mg, or placebo, titrated in weekly 0.6 mg steps, all with a dietary deficit and increased physical activity | 423 on 3.0 mg, 211 on 1.8 mg, 212 on placebo; adults with overweight or obesity and type 2 diabetes | 56 weeks |
| LEAD-6 (Buse, 2009)8 | 1.8 mg once a day, or exenatide 10 microg twice a day, added to metformin, sulphonylurea or both; open-label | 233 on liraglutide, 231 on exenatide; adults with inadequately controlled type 2 diabetes | 26 weeks |
| Liraglutide for adolescents with obesity, NN8022-4180 (Kelly, 2020)9 | 3.0 mg, or placebo, with lifestyle therapy | 125 on liraglutide, 126 on placebo; adolescents aged 12 to <18 with obesity | 56 weeks, then 26 weeks of follow-up |
| STEP 8 (Rubino, 2022)10 | 3.0 mg once daily with a 4-week escalation, or semaglutide 2.4 mg once weekly with a 16-week escalation, or placebo | 127 on liraglutide, 126 on semaglutide, 85 on pooled placebo; 338 adults with overweight or obesity without diabetes | 68 weeks |
In STEP 8 the mean weight change at 68 weeks was –6.4% with liraglutide and –15.8% with semaglutide.10
How liraglutide pens are stored
The Victoza label gives storage before first use in a refrigerator at 36°F to 46°F (2°C to 8°C), not in the freezer.1 After first use it gives 30 days at 59°F to 86°F (15°C to 30°C) or in a refrigerator, with the cap on and without a needle attached.1
The EMA Victoza text gives a shelf life of 30 months in a refrigerator (2°C–8°C), and 1 month after first use, below 30°C or in a refrigerator (2°C–8°C).3
Frequently asked questions
What if a liraglutide dose is missed?
The Victoza label says to resume the once-daily regimen with the next scheduled dose, without an extra dose or a higher dose to make up for the missed one.1 The Saxenda label says to resume the once-daily regimen with the next scheduled dose, without an extra dose, and, if more than 3 days have passed since the last dose, to restart at 0.6 mg daily and follow the escalation schedule again.2
Is there a powder form of liraglutide to mix?
No label, trial or stability data for a powder or compounded liraglutide turned up in DailyMed, the EMA Victoza and Saxenda product information, PubMed or ClinicalTrials.gov.
References
- Novo Nordisk (DailyMed). These highlights do not include all the information needed to use VICTOZA ® safely and effectively. See full prescribing information for VICTOZA. VICTOZA (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010. 2025. dailymed.nlm.nih.gov
- Novo Nordisk (DailyMed). These highlights do not include all the information needed to use SAXENDA ® safely and effectively. See full prescribing information for SAXENDA. SAXENDA (liraglutide) injection, for subcutaneous use Initial U.S. Approval: 2010. 2026. dailymed.nlm.nih.gov
- EMA. Victoza, INN-liraglutide. ema.europa.eu
- PubMed. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. 2015. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01272219: Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes. 2015. clinicaltrials.gov
- PubMed. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. 2015. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01272232: Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes. 2015. clinicaltrials.gov
- PubMed. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). 2009. pubmed.ncbi.nlm.nih.gov
- PubMed. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity. 2020. pubmed.ncbi.nlm.nih.gov
- JAMA via PMC. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. pmc.ncbi.nlm.nih.gov